Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.

Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.

<p>Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.</p>

Збережено в:

Бібліографічні деталі
Автор:	Seyed Reza Mousavi (13223324) (author)
Інші автори:	Alihasan Rahmani (22676321) (author), Maryam Amini Pouya (22676324) (author), Elnaz Zabihi Eidgahi (22676327) (author), Mohamad Delirrad (22676330) (author), Hamed Hosseini (3480455) (author), Alireza Ghassemi Toussi (22676333) (author), Behnaz Hedayatjoo (22676336) (author), Seyyedeh Maryam Afshani (22676339) (author), Mohammad Amin Ghobadi (22676342) (author), Mohammad Reza Shahidi (22676345) (author), Seyed Amirhossein Mousavi (22676348) (author), Maryam Barghbani (22676351) (author), Mahdi Jannati Yazdan Abad (22676354) (author)
Опубліковано:	2025
Предмети:	Medicine Cell Biology Neuroscience Physiology Pharmacology Biotechnology Immunology Science Policy Mental Health patients received either day monitoring period total antivenom consumption treating snakebite envenomation antivenom units administered razi antivenom group snakebite envenomation razi antivenom razi group antivenom infusion 49 units 40 units snafab antivenom razi antivenoms snafab group serum sickness recovery rate primary endpoint muscle weakness mean number may 15th april 17th anaphylactic shock adverse events 98 %). 92 ). 27 ). 100 percent
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
за авторством: Seyed Reza Mousavi (13223324)
Опубліковано: (2025)

Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
за авторством: Seyed Reza Mousavi (13223324)
Опубліковано: (2025)

Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
за авторством: Seyed Reza Mousavi (13223324)
Опубліковано: (2025)

Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
за авторством: Seyed Reza Mousavi (13223324)
Опубліковано: (2025)

Size exclusion chromatography (SEC) analysis of the three antivenoms and control proteins.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

SVMP activity of <i>E. ocellatus s. str.</i> and <i>E. romani</i> venoms and their neutralisation by the three different antivenoms.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

Plasma clotting activity of <i>E. ocellatus s. str.</i> and <i>E. romani</i> venoms and their neutralisation by the three different antivenoms.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

PLA<sub>2</sub> activity of <i>E. ocellatus s. str.</i> and <i>E. romani</i> venoms and their neutralisation by the three different antivenoms.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

The titre of three antivenoms against <i>E. ocellatus s. str.</i> and <i>E. romani</i> venoms determined by end-point titration ELISA.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

Antivenom efficacy against <i>E. romani</i> (Nigeria) in a murine pre-incubation model. The efficacy of EchiTAbG, SAIMR Echis and Echiven against <i><i>E. romani</i></i> (Nigeria) reported as ED<sub>50</sub> (µL), potency (mg/mL) and volume of antivenom per mg of venom (µL/mg)<i>.</i> 95% confidence intervals indicated in parentheses.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

An overview of the antivenoms used in this study. The table shows manufacturer information, batch/lot numbers and expiry dates, composition of antivenom immunoglobulins, protein concentration, and the venom reported to be used in immunisation and their geographical origin (where known) as indicated on the inserts of the products. Asterisk indicates assumed <i><i>E. ocellatus sensu lato.</i></i> ^ Although stated as <i><i>E. carinatus</i></i> in the product insert, this now refers to <i><i>E. pyramidum</i></i> due to taxonomic changes.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

Histopathological changes in the skin after administration of <i>M. l. obtusa</i> (MLO) venom, a venom antivenom mixture, and antivenom injected locally following venom exposure.
за авторством: Gevorg Avagyan (22601121)
Опубліковано: (2025)

Antivenom availability and reported challenges in snakebite case management among healthcare professionals in Afar Region, Ethiopia.
за авторством: Abebe M. Aga (22655919)
Опубліковано: (2025)

Dermal lesions induced by <i>M. l. obtusa</i> (MLO) venom are inhibited by ovine-derived experimental antivenom.
за авторством: Gevorg Avagyan (22601121)
Опубліковано: (2025)

Histopathological changes in the spleen after injection of <i>M. l. obtusa</i> (MLO) venom and venom/antivenom mixture.
за авторством: Gevorg Avagyan (22601121)
Опубліковано: (2025)

ED<sub>100</sub> survival times.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

Maximum likelihood phylogeny of the <i>Echis ocellatus</i> group inferred from 1433 base pairs of mitochondrial CYTB and NADH4 sequence.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

PLA<sub>2</sub> assay optimisation.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

Preclinical assays survival times.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

Plasma clotting assay raw data.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

SVMP assay raw data.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

PLA2 assay raw data.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

ELISA raw data.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

BCA assay raw data.
за авторством: Rebecca J. Edge (12732488)
Опубліковано: (2025)

APTT, PT and INR levels after the intravenous administration of PBS (Control), Venom and Antivenom + Venom (AnV + V) (experimental repeats–6, mean ± SEM; one-way ANOVA with Dunnett’s multiple comparison test).
за авторством: Gevorg Avagyan (22601121)
Опубліковано: (2025)

RBC, HGB, HCT levels after the intravenous administration of PBS (Control), Venom and Antivenom + Venom (AnV + V) (experimental repeats–6, mean ± SEM; one-way ANOVA with Dunnett’s multiple comparison test, p* < 0.05; p*** < 0.001; p**** < 0.0001).
за авторством: Gevorg Avagyan (22601121)
Опубліковано: (2025)

Post-discharge follow-up practices and estimates of snakebite severity.
за авторством: Abebe M. Aga (22655919)
Опубліковано: (2025)

Professional distribution and experience of healthcare providers involved in snakebite management in the study hospitals.
за авторством: Abebe M. Aga (22655919)
Опубліковано: (2025)

Training status, training needs, and confidence levels in snakebite management among healthcare professionals.
за авторством: Abebe M. Aga (22655919)
Опубліковано: (2025)

Cross-tabulation of healthcare professionals’ snakebite awareness and training status by profession, with corresponding p-values.
за авторством: Abebe M. Aga (22655919)
Опубліковано: (2025)

Case screening approaches, first-line treatment practices, and estimated frequency of snakebite case presentations among healthcare professionals.
за авторством: Abebe M. Aga (22655919)
Опубліковано: (2025)

Tissue damage in Spleen and Skin: + (mild), ++ (moderate), +++ (severe).
за авторством: Gevorg Avagyan (22601121)
Опубліковано: (2025)

Complete Blood Count (CBC) Parameters Across Experimental Groups (experimental repeats–6, mean ± SEM; one-way ANOVA with Dunnett’s multiple comparison test).
за авторством: Gevorg Avagyan (22601121)
Опубліковано: (2025)

Coagulation assay raw data by group and animal.
за авторством: Gevorg Avagyan (22601121)
Опубліковано: (2025)

Complete blood count (CBC) raw data organized by group and animal.
за авторством: Gevorg Avagyan (22601121)
Опубліковано: (2025)

Crotalidae polyvalent immune Fab (ovine) dosing in <i>Agkistrodon contortrix</i> envenomation: a single-center retrospective cohort study
за авторством: Kevin Baumgartner (14075764)
Опубліковано: (2025)

Distribution of number of antivenom doses administered to patients (n = 87).
за авторством: Jean-Philippe Chippaux (790696)
Опубліковано: (2025)

<b>Strategic Point Coverage for Scorpion Accident Care: Methodological Considerations and Application in São Paulo State, Brazil</b>Santos P
за авторством: Gabriella Pereira dos Santos (22054562)
Опубліковано: (2025)

<b>Supplementary Material – </b> <b>Thiophene-triazole hybrids inhibit the major toxic activities </b><b>of </b><b><i>Bothrops jararacussu</i></b><b> venom</b>
за авторством: Brenda Bairral de Oliveira (22447117)
Опубліковано: (2025)

<b>Supplementary Material – Thiophene-triazole hybrids inhibit the major toxic activities </b><b>of </b><b><i>Bothrops jararacussu</i></b><b> venom</b>
за авторством: Brenda Bairral de Oliveira (22447117)
Опубліковано: (2025)